Boston Scientific Corp
I · Analiza AI
Pe scurt
Boston Scientific designs and sells specialized medical equipment that doctors use during minimally-invasive procedures — think catheters, stents, implants, and electronic devices that treat conditions in the heart, digestive tract, urinary system, and nervous system [Boston Scientific]. Their products help cardiologists open blocked arteries, urologists treat bladder problems, and pain specialists manage chronic pain through implanted nerve stimulators [Boston Scientific].
Boston Scientific is a $84.4 billion medical device company that makes products for heart procedures, digestive system treatments, urology, and pain management [Yahoo Finance]. The company reported strong revenue growth of 19.9% year-over-year and recently announced a $2 billion share buyback alongside a $1.5 billion investment in MiRus, a company developing a new heart valve technology [Yahoo Finance]. Recent clinical trial success with its SEISMIQ 4CE device for treating severely calcified heart arteries positions the company well in a challenging cardiac niche [Simply Wall St].
Boston Scientific is financially stable with strong cash generation, though debt levels are moderate and returns on invested capital remain below 10% [Yahoo Finance].
Scor Sentinellis
6.3/10
Moderate concerns
Capitalizare bursieră
$84.4B
Venituri (12 luni)
$20.1B
II · Știri recente
Ce a mișcat prețul
6 stories · ranked by relevance
- macro2026-05-20
Boston Scientific Trial Success Adds Weight To SEISMIQ 4CE And BSX Valuation
Simply Wall St
- macro2026-05-20
Boston Scientific Corporation (BSX) Fell Due to Weak Results
Yahoo Finance
- macro2026-05-20
Baird Maintains Bullish View on Boston Scientific (BSX) Despite Lower Target
Yahoo Finance
- macro2026-05-19
Wall Street Bulls Look Optimistic About Boston Scientific (BSX): Should You Buy?
Yahoo Finance
- macro2026-05-19
FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
Yahoo Finance
- macro2026-05-18
Boston Scientific announces strategic investment in MiRus LLC
Yahoo Finance
Premium · gratuit cu orice cont
The company's stock underperformed in Q1 2026 as part of broader market weakness driven by geopolitical conflicts, private credit concerns, government shutdown, and AI uncertainty, with Boston Scientific being among top holdings in funds that lost over 11% during the period [Yahoo Finance].
Riscuri
4
Oportunități
6
Conducere
10
Încă 19 constatări în raportul complet — gratuit cu orice cont.
Deblochează analiza completă Boston Scientific Corp
Fă-ți un cont gratuit ca să vezi raportul complet generat de AI, cu surse citate în text.
- 4 riscuri și 6 oportunități — fiecare cu sursa lui
- Peste 100 de indicatori financiari, cu grafice și comparații
- Rezumate complete ale știrilor, cu linkuri către surse
- Echipa de conducere și remunerația
- Export PDF pentru citit offline
III · Companii similare
Ai putea citi și
Same sector · Healthcare or comparable health
Vrei compania asta pe lista ta?